← Leaderboards
Randy E Sacco
Iowa State University
$1,038,687
Attributed
$2,077,373
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $575.6K · FY2019–22$1M$750K$500K$250K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$2,077,373 · 1
By mechanism
R01$2,077,373 · 1
Top collaborators
- Jodi Mcgill4 shared
Most similar at Iowa State University
Same institution · by research overlap
- Balaji Narasimhan$10,147,669
- Marian L Kohut$5,498,591
- Jodi McGill$1,268,187
- Maria P Torres-Gonzalez$53,588
- Michael J Wannemuehler$142,961
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteAdultAdjuvantAgonistAllergic Airway DiseaseAnhydridesAnimalsAffectAntigensAntiviral ImmunityBaseBiomaterial CompatibilityBurden Of IllnessCattleCd8-Positive T-LymphocytesChildCold ChainsAntibody ResponseDesignDoseElderlyEncapsulatedExperimental StudyFamily Suidae
Grant awards (4)
Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate$528,103
R01 · FY2022 · HD
Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate$575,637
R01 · FY2021 · HD
Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate$437,042
R01 · FY2020 · HD
Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate$536,591
R01 · FY2019 · HD